

**THRU ONLINE FILING**

December 5, 2025

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 023  
Scrip Code – 524494

National Stock Exchange India Limited,  
Exchange Plaza, C-1, Block-G,  
Bandra Kurla Complex, Bandra – (East).  
Mumbai-400051.  
Scrip Code : IPCALAB

Dear Sirs,

**Re: Inspection of Company's Active Pharmaceutical Ingredients (APIs) manufacturing facility situated at Tarapur (Palghar-Maharashtra) by US FDA**

This is to inform you that the US FDA conducted the inspection of the Company's Active Pharmaceutical Ingredients (APIs) manufacturing facility situated at Tarapur (Palghar-Maharashtra) from 1<sup>st</sup> December, 2025 to 5<sup>th</sup> December, 2025. At the conclusion of the inspection, US FDA has issued a Form 483 with 3 (three) observations.

The Company will submit its comprehensive response on these observations to the US FDA within the stipulated time and shall work closely with the agency to resolve these issues at the earliest.

The Company takes the quality and compliance issues with utmost importance and remains committed to maintain the highest standards of quality and compliance across all its manufacturing facilities.

Thanking you

Yours faithfully  
For Ipca Laboratories Limited

Harish P. Kamath  
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.  
[www.ipca.com](http://www.ipca.com)

125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005  
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444  
E: [ipca@ipca.com](mailto:ipca@ipca.com) CIN: L24239MH1949PLC007837